RDHL
RedHill Biopharma Ltd.
Price Chart
Latest Quote
$0.81
+0.03 (+3.67%)
Current Price
| Previous Close | $0.78 |
| Open | $0.79 |
| Day High | $0.86 |
| Day Low | $0.78 |
| Volume | 677,965 |
Stock Information
| Shares Outstanding | 5.19M |
| Total Debt | $1.07M |
| Cash Equivalents | $3.97M |
| Revenue | $286K |
| Net Income | $-8.08M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $4.22M |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.24M |
| Sales | $286K |
| Income | $-8.08M |
| Book/sh | $0.84 |
| Cash/sh | $0.76 |
| Employees | 13 |
Financial Ratios
| Quick Ratio | 0.29 |
| Current Ratio | 0.34 |
| Debt/Eq | 25.07 |
Returns & Margins
| ROA | -22.79% |
| Gross Margin | 100.00% |
| Operating Margin | -2765.38% |
| Profit Margin | -150.00% |
Ownership
| Institutional Ownership | 9.99% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 27.13 |
| P/S | 14.77 |
| P/B | 0.97 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.93 |
| SMA50 | $0.94 |
| SMA200 | $1.17 |
| RSI | 34.65 |
| ATR | 0.0911 |
| Shares Float | 4.00M |
| Short Float | 0.44% |
| Short Ratio | 0.23 |
| Volatility | 4.97 |
| Rel Volume | 1.39 |
Performance History
| Week | -11.62% |
| Month | -12.28% |
| Quarter | -8.33% |
| 6 Months | -32.45% |
| YTD | -20.97% |
| Year | -53.93% |
| 3 Years | -98.36% |
| 5 Years | -99.99% |
| 10 Years | -99.99% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.81 | 678,000 |
| 2026-06-17 | $0.79 | 56,300 |
| 2026-06-16 | $0.79 | 144,300 |
| 2026-06-15 | $0.83 | 1,060,900 |
| 2026-06-12 | $0.81 | 185,700 |
| 2026-06-11 | $0.92 | 322,300 |
| 2026-06-10 | $0.88 | 316,300 |
| 2026-06-09 | $0.80 | 5,937,600 |
| 2026-06-08 | $1.02 | 150,700 |
| 2026-06-05 | $1.03 | 63,100 |
| 2026-06-04 | $1.00 | 114,600 |
| 2026-06-03 | $1.00 | 169,000 |
| 2026-06-02 | $1.01 | 172,700 |
| 2026-06-01 | $1.00 | 24,900 |
| 2026-05-29 | $1.00 | 32,900 |
| 2026-05-28 | $1.00 | 29,000 |
| 2026-05-27 | $1.01 | 119,300 |
| 2026-05-26 | $1.01 | 90,000 |
| 2026-05-22 | $0.98 | 58,900 |
| 2026-05-21 | $0.94 | 18,400 |
| 2026-05-20 | $0.92 | 64,700 |
| 2026-05-19 | $0.93 | 48,900 |
About RedHill Biopharma Ltd.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $286,000 | $0 | $0 | $61,800,000 |
| Operating Revenue | $286,000 | $0 | $0 | $61,800,000 |
| Reconciled Cost Of Revenue | - | $3,192,000 | $3,459,000 | $33,337,000 |
| Cost Of Revenue | - | $3,192,000 | $3,459,000 | $33,337,000 |
| Expenses | ||||
| Interest Expense | $19,000 | $44,000 | $63,000 | $41,333,000 |
| Total Expenses | $8,195,000 | $6,475,000 | $9,547,000 | $104,644,000 |
| Other Income Expense | $1,160,000 | $8,257,000 | $-7,143,000 | $13,382,000 |
| Net Non Operating Interest Income Expense | $-1,331,000 | $-1,422,000 | $-1,807,000 | $-42,207,000 |
| Total Other Finance Cost | $1,335,000 | $1,457,000 | $1,835,000 | $1,014,000 |
| Interest Expense Non Operating | $19,000 | $44,000 | $63,000 | $41,333,000 |
| Operating Expense | $8,195,000 | $6,475,000 | $9,547,000 | $71,307,000 |
| General And Administrative Expense | $6,172,000 | $4,887,000 | $6,018,000 | $54,970,000 |
| Selling And Marketing Expense | - | $1,002,000 | $2,095,000 | $9,058,000 |
| Other Non Operating Income Expenses | - | - | $8,600,000 | - |
| Other Operating Expenses | - | - | $-44,064,000 | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-8,080,000 | $360,000 | $-18,498,000 | $-71,669,000 |
| Net Interest Income | $-1,331,000 | $-1,422,000 | $-1,807,000 | $-42,207,000 |
| Interest Income | $23,000 | $79,000 | $91,000 | $140,000 |
| Normalized Income | $-9,273,000 | $-5,997,890 | $-11,355,000 | $-85,051,000 |
| Net Income From Continuing And Discontinued Operation | $-429,000 | $-8,268,000 | $23,916,000 | $-71,669,000 |
| Total Operating Income As Reported | $-7,942,000 | $-6,475,000 | $-9,548,000 | $-42,844,000 |
| Net Income Common Stockholders | $-429,000 | $-8,268,000 | $23,916,000 | $-71,669,000 |
| Net Income | $-429,000 | $-8,268,000 | $23,916,000 | $-71,669,000 |
| Net Income Including Noncontrolling Interests | $-429,000 | $-8,268,000 | $23,916,000 | $-71,669,000 |
| Net Income Discontinuous Operations | $7,651,000 | $-8,628,000 | $42,414,000 | - |
| Net Income Continuous Operations | $-8,080,000 | $360,000 | $-18,497,000 | $-71,669,000 |
| Pretax Income | $-8,080,000 | $360,000 | $-18,497,000 | $-71,669,000 |
| Special Income Charges | $0 | $0 | $-1,459,000 | $0 |
| Earnings From Equity Interest | $-33,000 | $0 | $0 | - |
| Interest Income Non Operating | $23,000 | $79,000 | $91,000 | $140,000 |
| Operating Income | $-7,909,000 | $-6,475,000 | $-9,547,000 | $-42,844,000 |
| Gross Profit | - | $4,851,000 | $3,071,000 | $28,463,000 |
| Per Share | ||||
| Diluted EPS | - | $0.00 | $100.00 | $-1200.00 |
| Basic EPS | - | - | $100.00 | $-1200.00 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $1,899,110 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-8,845,000 | $-7,234,000 | $-9,301,000 | $-35,564,000 |
| Total Unusual Items | $1,193,000 | $8,257,000 | $-7,143,000 | $13,382,000 |
| Total Unusual Items Excluding Goodwill | $1,193,000 | $8,257,000 | $-7,143,000 | $13,382,000 |
| Reconciled Depreciation | $409,000 | $619,000 | $1,990,000 | $8,154,000 |
| EBITDA (Bullshit earnings) | $-7,652,000 | $1,023,000 | $-16,444,000 | $-22,182,000 |
| EBIT | $-8,061,000 | $404,000 | $-18,434,000 | $-30,336,000 |
| Diluted NI Availto Com Stockholders | $-429,000 | $-8,268,000 | $23,916,000 | $-71,669,000 |
| Gain On Sale Of Security | $1,193,000 | $8,257,000 | $-5,684,000 | $13,382,000 |
| Research And Development | $2,023,000 | $1,588,000 | $3,529,000 | $7,279,000 |
| Selling General And Administration | $6,172,000 | $4,887,000 | $6,018,000 | $64,028,000 |
| Other Gand A | $3,892,000 | $2,622,000 | $2,916,000 | $20,690,000 |
| Salaries And Wages | $2,280,000 | $2,265,000 | $3,102,000 | $34,280,000 |
| Diluted Average Shares | - | $1,289,983 | $259,122 | $61,630 |
| Basic Average Shares | - | $1,289,983 | $259,122 | $61,630 |
| Other Special Charges | - | $2,359,000 | $1,459,000 | - |
| Gain On Sale Of Business | - | - | $35,500,000 | - |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-1,023,000 | $-10,230,000 | $-3,509,000 | $-114,026,000 |
| Total Assets | $25,345,000 | $18,043,000 | $23,047,000 | $158,870,000 |
| Total Non Current Assets | $18,817,000 | $6,132,000 | $6,907,000 | $72,970,000 |
| Other Non Current Assets | $170,000 | $148,000 | $147,000 | $150,000 |
| Non Current Accounts Receivable | $201,000 | - | - | - |
| Goodwill And Other Intangible Assets | $5,291,000 | $5,547,000 | $5,578,000 | $65,626,000 |
| Other Intangible Assets | $5,291,000 | $5,547,000 | $5,578,000 | $65,626,000 |
| Current Assets | $6,528,000 | $11,911,000 | $16,140,000 | $85,900,000 |
| Prepaid Assets | $78,000 | $77,000 | $1,310,000 | $1,033,000 |
| Inventory | $0 | $3,651,000 | $4,389,000 | $11,009,000 |
| Receivables | $2,479,000 | $3,566,000 | $4,082,000 | $37,875,000 |
| Other Receivables | $2,400,000 | $1,027,000 | $1,491,000 | $3,354,000 |
| Accounts Receivable | $79,000 | $2,539,000 | $2,591,000 | $34,521,000 |
| Cash Cash Equivalents And Short Term Investments | $3,971,000 | $4,617,000 | $5,569,000 | $19,983,000 |
| Cash And Cash Equivalents | $3,971,000 | $4,617,000 | $5,569,000 | $19,968,000 |
| Cash Equivalents | $2,623,000 | $2,735,000 | $0 | $6,645,000 |
| Cash Financial | $1,348,000 | $1,882,000 | $5,569,000 | $13,323,000 |
| Restricted Cash | - | $0 | $790,000 | $16,000,000 |
| Debt | ||||
| Total Debt | $1,070,000 | $356,000 | $1,173,000 | $122,691,000 |
| Long Term Debt And Capital Lease Obligation | $900,000 | $3,000 | $455,000 | $6,443,000 |
| Current Debt And Capital Lease Obligation | $170,000 | $353,000 | $718,000 | $116,248,000 |
| Net Debt | - | - | - | $95,248,000 |
| Current Debt | - | - | - | $115,216,000 |
| Other Current Borrowings | - | - | - | $115,216,000 |
| Long Term Debt | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $21,077,000 | $22,726,000 | $20,978,000 | $207,270,000 |
| Total Non Current Liabilities Net Minority Interest | $1,856,000 | $503,000 | $995,000 | $9,816,000 |
| Other Non Current Liabilities | $956,000 | $500,000 | $540,000 | $750,000 |
| Current Liabilities | $19,221,000 | $22,223,000 | $19,983,000 | $197,454,000 |
| Other Current Liabilities | $2,180,000 | $2,016,000 | $841,000 | $114,000 |
| Payables And Accrued Expenses | $10,024,000 | $10,056,000 | $7,043,000 | $31,555,000 |
| Payables | $6,416,000 | $7,861,000 | $3,278,000 | $15,387,000 |
| Accounts Payable | $6,416,000 | $7,861,000 | $3,278,000 | $4,230,000 |
| Derivative Product Liabilities | - | - | $741,000 | $2,623,000 |
| Tradeand Other Payables Non Current | - | - | - | $0 |
| Other Payable | - | - | - | $11,157,000 |
| Equity | ||||
| Common Stock Equity | $4,268,000 | $-4,683,000 | $2,069,000 | $-48,400,000 |
| Total Equity Gross Minority Interest | $4,268,000 | $-4,683,000 | $2,069,000 | $-48,400,000 |
| Stockholders Equity | $4,268,000 | $-4,683,000 | $2,069,000 | $-48,400,000 |
| Retained Earnings | $-413,755,000 | $-414,801,000 | $-407,735,000 | $-433,860,000 |
| Long Term Equity Investment | $12,050,000 | $0 | - | - |
| Other | ||||
| Ordinary Shares Number | $50,923,261,000 | $12,986,621,000 | $7,869,853,200 | $931,962,000 |
| Share Issued | $50,923,261,000 | $12,986,621,000 | $7,869,853,200 | $931,962,000 |
| Tangible Book Value | $-1,023,000 | $-10,230,000 | $-3,509,000 | $-114,026,000 |
| Invested Capital | $4,268,000 | $-4,683,000 | $2,069,000 | $66,816,000 |
| Working Capital | $-12,693,000 | $-10,312,000 | $-3,843,000 | $-111,554,000 |
| Capital Lease Obligations | $1,070,000 | $356,000 | $1,173,000 | $7,475,000 |
| Total Capitalization | $4,268,000 | $-4,683,000 | $2,069,000 | $-48,400,000 |
| Additional Paid In Capital | $270,382,000 | $375,082,000 | $388,363,000 | $382,625,000 |
| Capital Stock | $147,641,000 | $35,036,000 | $21,441,000 | $2,835,000 |
| Common Stock | $147,641,000 | $35,036,000 | $21,441,000 | $2,835,000 |
| Long Term Capital Lease Obligation | $900,000 | $3,000 | $455,000 | $6,443,000 |
| Current Capital Lease Obligation | $170,000 | $353,000 | $718,000 | $1,032,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $543,000 | $510,000 | $727,000 | $1,667,000 |
| Current Provisions | $6,304,000 | $9,288,000 | $10,654,000 | $47,870,000 |
| Current Accrued Expenses | $3,608,000 | $2,195,000 | $3,765,000 | $16,168,000 |
| Investments And Advances | $12,050,000 | $0 | - | - |
| Investmentsin Joint Venturesat Cost | $12,050,000 | $0 | - | - |
| Net PPE | $1,105,000 | $437,000 | $1,182,000 | $7,194,000 |
| Accumulated Depreciation | $-1,404,000 | $-1,312,000 | $-1,245,000 | $-1,076,000 |
| Gross PPE | $2,509,000 | $1,749,000 | $2,427,000 | $8,270,000 |
| Leases | $1,436,000 | $681,000 | $1,152,000 | $6,009,000 |
| Machinery Furniture Equipment | $1,073,000 | $1,068,000 | $1,275,000 | $2,261,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $0 | $2,830,000 | $3,328,000 | $6,827,000 |
| Work In Process | $0 | $308,000 | $233,000 | $2,385,000 |
| Raw Materials | $0 | $513,000 | $828,000 | $1,797,000 |
| Other Short Term Investments | - | - | $0 | $15,000 |
| Other Properties | - | - | - | $5,630,000 |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-9,656,000 | $-9,378,000 | $-35,831,000 | $-29,383,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-9,651,000 | $-9,369,000 | $-35,820,000 | $-29,185,000 |
| Cash Flow From Continuing Operating Activities | $-9,651,000 | $-9,369,000 | $-35,820,000 | $-29,185,000 |
| Operating Gains Losses | $-8,119,000 | $-6,775,000 | $-47,211,000 | $-12,504,000 |
| Investing Activities | ||||
| Capital Expenditure | $-5,000 | $-9,000 | $-11,000 | $-198,000 |
| Investing Cash Flow | $1,691,000 | $-9,000 | $4,000 | $8,302,000 |
| Cash Flow From Continuing Investing Activities | $1,691,000 | $-9,000 | $4,000 | $8,302,000 |
| Net Other Investing Changes | $-304,000 | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $7,764,000 | $8,263,000 | $13,959,000 | $23,806,000 |
| Financing Cash Flow | $7,317,000 | $8,417,000 | $21,439,000 | $11,453,000 |
| Cash Flow From Continuing Financing Activities | $7,317,000 | $8,417,000 | $21,439,000 | $11,453,000 |
| Net Common Stock Issuance | $7,764,000 | $8,263,000 | $13,959,000 | $23,806,000 |
| Common Stock Issuance | $7,764,000 | $8,263,000 | $13,959,000 | $23,806,000 |
| Net Other Financing Charges | - | $790,000 | $8,655,000 | $-10,878,000 |
| Other | ||||
| Repayment Of Debt | $-447,000 | $-636,000 | $-1,175,000 | $-1,475,000 |
| Interest Paid Supplemental Data | $18,000 | $55,000 | $367,000 | $8,182,000 |
| End Cash Position | $3,971,000 | $4,617,000 | $5,569,000 | $19,968,000 |
| Beginning Cash Position | $4,617,000 | $5,569,000 | $19,968,000 | $29,474,000 |
| Effect Of Exchange Rate Changes | $-2,000 | $9,000 | $-22,000 | $-76,000 |
| Changes In Cash | $-644,000 | $-961,000 | $-14,377,000 | $-9,430,000 |
| Net Issuance Payments Of Debt | $-447,000 | $-636,000 | $-1,175,000 | $-1,475,000 |
| Net Long Term Debt Issuance | $-447,000 | $-636,000 | $-1,175,000 | $-1,475,000 |
| Long Term Debt Payments | $-447,000 | $-636,000 | $-1,175,000 | $-1,475,000 |
| Net Investment Purchase And Sale | $0 | $0 | $15,000 | $8,500,000 |
| Net Business Purchase And Sale | $2,000,000 | $0 | $0 | - |
| Sale Of Business | $2,000,000 | $0 | $0 | - |
| Net PPE Purchase And Sale | $-5,000 | $-9,000 | $-11,000 | $-198,000 |
| Purchase Of PPE | $-5,000 | $-9,000 | $-11,000 | $-198,000 |
| Change In Working Capital | $-1,969,000 | $2,053,000 | $-15,619,000 | $8,008,000 |
| Change In Other Working Capital | $-2,984,000 | $-1,366,000 | $-37,216,000 | $17,159,000 |
| Change In Payables And Accrued Expense | $2,042,000 | $932,000 | $-14,306,000 | $-10,381,000 |
| Change In Accrued Expense | $2,479,000 | $3,042,000 | $-13,354,000 | $-2,947,000 |
| Change In Payable | $-437,000 | $-2,110,000 | $-952,000 | $-7,434,000 |
| Change In Account Payable | $-437,000 | $-2,110,000 | $-952,000 | $-7,434,000 |
| Change In Prepaid Assets | $-2,911,000 | $1,697,000 | $1,586,000 | $274,000 |
| Change In Inventory | $-375,000 | $738,000 | $2,387,000 | $3,801,000 |
| Change In Receivables | $2,259,000 | $52,000 | $31,930,000 | $-2,845,000 |
| Changes In Account Receivables | $2,259,000 | $52,000 | $31,930,000 | $-2,845,000 |
| Stock Based Compensation | $457,000 | $665,000 | $1,647,000 | $5,675,000 |
| Depreciation Amortization Depletion | $409,000 | $619,000 | $1,990,000 | $8,154,000 |
| Depreciation And Amortization | $409,000 | $619,000 | $1,990,000 | $8,154,000 |
| Amortization Cash Flow | $25,000 | $31,000 | $545,000 | $6,018,000 |
| Amortization Of Intangibles | $25,000 | $31,000 | $545,000 | $6,018,000 |
| Depreciation | $384,000 | $588,000 | $1,445,000 | $2,136,000 |
| Earnings Losses From Equity Investments | $33,000 | $0 | $0 | - |
| Gain Loss On Investment Securities | $-262,000 | $-6,771,000 | $8,852,000 | $-12,464,000 |
| Net Foreign Currency Exchange Gain Loss | $93,000 | $-4,000 | $19,000 | $-40,000 |
| Gain Loss On Sale Of Business | $-7,983,000 | $0 | $-56,082,000 | $0 |
| Net Income From Continuing Operations | $-429,000 | $-8,268,000 | $23,916,000 | $-71,669,000 |
| Other Non Cash Items | - | $2,337,000 | $-543,000 | $33,151,000 |
| Proceeds From Stock Option Exercised | - | - | $0 | $0 |
| Sale Of Investment | - | - | $15,000 | $8,500,000 |
| Issuance Of Debt | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
| Net Intangibles Purchase And Sale | - | - | - | $0 |
| Purchase Of Intangibles | - | - | - | $0 |
| Unrealized Gain Loss On Investment Securities | - | - | - | $0 |
| Purchase Of Investment | - | - | - | - |
Fetched: 2026-06-20